DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.

Ott, Katja

DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. [electronic resource] - Annals of surgical oncology Sep 2011 - 2688-98 p. digital

Publication Type: Journal Article

1534-4681

10.1245/s10434-011-1601-y doi


Adenocarcinoma--drug therapy
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Cisplatin--administration & dosage
Clinical Trials, Phase II as Topic
DNA Repair--genetics
DNA, Neoplasm--genetics
Esophageal Neoplasms--drug therapy
Female
Fluorouracil--administration & dosage
Follow-Up Studies
Genotype
Humans
Male
Methylenetetrahydrofolate Reductase (NADPH2)--genetics
Middle Aged
Neoadjuvant Therapy
Neoplasm Recurrence, Local--drug therapy
Neoplasm Staging
Polymerase Chain Reaction
Polymorphism, Genetic--genetics
Prospective Studies
Retrospective Studies
Stomach Neoplasms--drug therapy
Survival Rate
Treatment Outcome